未登录

L

Lyubomir T. Vassilev

cancer research uk

H指数:40

被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MOLECULAR CANCER THERAPEUTICS

IF5.5

2022-04-1134

OAAI

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-05-04119

OAAI

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells

IF6.9

2016-03-0138

OAAI

Constitutive autophagy contributes to resistance to TP53-mediated apoptosis in Epstein-Barr virus-positive latency III B-cell lymphoproliferations

IF14.3

2016-01-0629

OA

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence Implications for therapy

IF3.4

2014-10-3128

OAAI

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2014-08-0154

PREAI

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

CLINICAL CANCER RESEARCH

IF10.2

2014-07-1467

OAAI

Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo

内源性c-myc对于体内DNA损伤的p53-induced凋亡至关重要

CELL DEATH AND DIFFERENTIATION

IF15.4

2014-02-2890

OAAI

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2014-01-0785

OA

Antitumor activity of the MDM2 antagonist RG7388.

MOLECULAR CANCER THERAPEUTICS

IF5.5

2013-11-015

PRE

Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2013-08-14647

OAAI

Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2013-07-16532

PREAI

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2013-04-04381

OA

ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled A-helical Peptide Exhibits Potent in Vitro and in Vivo Efficacy in Xenograft Models of Human Cancer

EUROPEAN JOURNAL OF CANCER

IF7.1

2012-11-013

PREAI

FLT3/ITD acute myeloid leukemia (AML) cells show C-MYC- and PIM-1-mediated CDC25A overexpression despite the presence of intrinsic DNA damage

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Elevated MDM2 protein contributes to activity of MDM2 antagonists by enabling p53 induction of antitumor microRNAs

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Subtype and pathway specific responses to anticancer compounds in breast cancer

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2011-10-14420

OA

Heiser, Laura M.; Sadanandam, Anguraj; Kuo, Wen-Lin; Benz, Stephen C.; Goldstein, Theodore C.; Ng, Sam; Gibb, William J.; Wang, Nicholas J.; Ziyad, Safiyyah; Tong, Frances; Bayani, Nora; Hu, Zhi; Billig, Jessica I.; Dueregger, Andrea; Lewis, Sophia; Jakkula, Lakshmi; Korkola, James E.; Durinck, Steffen; Pepin, Francois; Guan, Yinghui; Purdom, Elizabeth; Neuvial, Pierre; Bengtsson, Henrik; Wood, Kenneth W.; Smith, Peter G.; Vassilev, Lyubomir T.; Hennessy, Bryan T.; Greshock, Joel; Bachman, Kurtis E.; Hardwicke, Mary Ann; Park, John W.; Marton, Laurence J.; Wolf, Denise M.; Collisson, Eric A.; Neve, Richard M.; Mills, Gordon B.; Speed, Terence P.; Feiler, Heidi S.; Wooster, Richard F.; Haussler, David; Stuart, Joshua M.; Gray, Joe W.; Spellman, Paul T.

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation

BRITISH JOURNAL OF CANCER

IF6.8

2011-08-2337

OAAI

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

MDM2拮抗剂Nutlin-3a增强细胞毒性药物在肉瘤细胞系中的抗肿瘤活性

IF3.4

2011-05-3067

OAAI

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

MOLECULAR CANCER

IF33.9

2011-05-0341

OAAI